Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Maria Martin Lopes

Cresskill, NJ Medical Doctor

NPI 1093969784 CMS profile 1388782

117 Truman Dr, Cresskill, NJ 07626

Open in the dashboard

General payments

$775,877

659 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maria Martin Lopes of Cresskill, NJ is reported in the CMS Open Payments database as having received $775,877 across 659 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $107,713 79
2024 General $93,924 81
2023 General $163,611 143
2022 General $107,073 73
2021 General $72,976 34
2020 General $92,487 60
2019 General $138,095 189

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maria Martin Lopes
  • New Jersey median
  • Middle half of New Jersey
  • National median

In program year 2025, general payments to Maria Martin Lopes were reported at $107,713. Among 31,834 New Jersey profiles paid that year, the median was $178 and the middle half received between $51 and $585.

Show as a table
Year Maria Martin Lopes New Jersey median Middle half National median
2019 $138,095 $150 $44–$542 $163
2020 $92,487 $110 $33–$349 $114
2021 $72,976 $125 $36–$419 $132
2022 $107,073 $142 $42–$480 $149
2023 $163,611 $156 $48–$510 $160
2024 $93,924 $167 $50–$562 $164
2025 $107,713 $178 $51–$585 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $161,375 200 payments
  2. Pfizer Inc. $101,310 58 payments
  3. Genzyme Corporation $70,124 35 payments
  4. EMD Serono, Inc. $51,043 28 payments
  5. Medtronic, Inc. $49,272 26 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $33,353 16 payments
  7. Regeneron Healthcare Solutions, Inc. $22,860 21 payments
  8. Genentech, Inc. $21,412 24 payments
  9. Genentech USA, Inc. $19,810 21 payments
  10. Otsuka America Pharmaceutical, Inc. $16,296 13 payments
  11. Other $229,024 217 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $569,213 178 payments
  2. Travel and Lodging $73,832 222 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $73,709 36 payments
  4. Honoraria $44,213 21 payments
  5. Food and Beverage $14,912 202 payments
Products named General payments · program years 2019–2025
  1. Kerendia $90,054 121 payments
  2. DUPIXENT Immunology $40,176 13 payments
  3. TALZENNA $25,761 12 payments
  4. DUPIXENT Inflammation And Immunology $21,235 20 payments
  5. Non-Covered $16,180 21 payments
  6. Xolair $13,215 13 payments
  7. XTANDI $11,877 6 payments
  8. Exparel $10,010 9 payments
  9. Zilretta $10,010 9 payments
  10. Iovera $10,010 9 payments
  11. Other $184,944 171 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

659 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record